Biomaterial Database

Moclobemide in the treatment of social phobia. 1996

D Nutt, and S A Montgomery

School of Medical Sciences, University of Bristol, UK.

Social phobia is a common disorder which is associated with considerable suffering and impairment. Effective treatments have now been developed and they represent an important advance in the management of the disorder. Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) which has an established place in the treatment of depression. The efficacy of moclobemide in social phobia has been demonstrated in short-term treatment for up to 12 weeks in three placebo-controlled studies. It has also proved to be effective in long-term treatment in a placebo-controlled study and in open treatment studies. This paper reviews the efficacy of moclobemide in social phobia.

UI	MeSH Term	Description	Entries
D008996	Monoamine Oxidase Inhibitors	A chemically heterogeneous group of drugs that have in common the ability to block oxidative deamination of naturally occurring monoamines. (From Gilman, et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 8th ed, p414)	MAO Inhibitor,MAO Inhibitors,Reversible Inhibitors of Monoamine Oxidase,Monoamine Oxidase Inhibitor,RIMA (Reversible Inhibitor of Monoamine Oxidase A),Reversible Inhibitor of Monoamine Oxidase,Inhibitor, MAO,Inhibitor, Monoamine Oxidase,Inhibitors, MAO,Inhibitors, Monoamine Oxidase
D010698	Phobic Disorders	Anxiety disorders in which the essential feature is persistent and irrational fear of a specific object, activity, or situation that the individual feels compelled to avoid. The individual recognizes the fear as excessive or unreasonable.	Claustrophobia,Neuroses, Phobic,Phobia, School,Phobias,Phobic Neuroses,Scolionophobia,Disorder, Phobic,Phobia,Phobic Disorder,School Phobia
D002986	Clinical Trials as Topic	Works about pre-planned studies of the safety, efficacy, or optimum dosage schedule (if appropriate) of one or more diagnostic, therapeutic, or prophylactic drugs, devices, or techniques selected according to predetermined criteria of eligibility and observed for predefined evidence of favorable and unfavorable effects. This concept includes clinical trials conducted both in the U.S. and in other countries.	Clinical Trial as Topic
D004305	Dose-Response Relationship, Drug	The relationship between the dose of an administered drug and the response of the organism to the drug.	Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801	Humans	Members of the species Homo sapiens.	Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D001549	Benzamides	BENZOIC ACID amides.
D020912	Moclobemide	A reversible inhibitor of monoamine oxidase type A; (RIMA); (see MONOAMINE OXIDASE INHIBITORS) that has antidepressive properties.	Apo-Moclobemide,Arima,Aurorex,Aurorix,Chem mart Moclobemide,DBL Moclobemide,Deprenorm,Feraken,GenRX Moclobemide,Healthsense Moclobemide,Manerix,Moclamine,Moclix,Moclobamide,Moclobemid AZU,Moclobemid Stada,Moclobemid von ct,Moclobemid-1A Pharma,Moclobemid-Puren,Moclobemid-ratiopharm,Moclobeta,Moclodura,Moclonorm,Novo-Moclobemide,Nu-Moclobemide,PMS-Moclobemide,Rimoc,Ro 11-1163,Ro-11-1163,Terry White Chemists Moclobemide,AZU, Moclobemid,Apo Moclobemide,Moclobemid 1A Pharma,Moclobemid Puren,Moclobemid ratiopharm,Moclobemid1A Pharma,Moclobemide, Chem mart,Moclobemide, DBL,Moclobemide, GenRX,Moclobemide, Healthsense,Novo Moclobemide,NovoMoclobemide,Nu Moclobemide,NuMoclobemide,PMS Moclobemide,Ro 11 1163,Stada, Moclobemid,von ct, Moclobemid